Journal
PHARMACEUTICS
Volume 10, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics10020040
Keywords
nose-to-brain delivery; neurological diseases; drug delivery systems; in situ-based gels; brain tumor; Alzheimer's disease
Categories
Funding
- Medical Research Council (Self-Initiated Research) (MRC)
- National Research Foundation (NRF), South Africa
Ask authors/readers for more resources
In situ-based gel drug delivery systems that can bypass the blood-brain barrier, deliver the therapeutics to the desired site, reduce peripheral toxicity and control drug release kinetics have been developed. Some of the therapeutics used to treat neurological diseases suffer from poor bioavailability. Preclinical reports from several researchers have proven that the delivery of drugs to the brain via the nose-to-brain route using in situ gels holds great promise. However, safety issues on the toxicity of the nasal mucosa, transportation of the drugs to specific brain regions and determination of the required dose are factors that must be considered when designing these gels. This review will be focused on in situ-based gels that are used for the delivery of therapeutics via the nose-to-brain route, preclinical reports and challenges.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available